Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs

Area of Science:

• Biomedical research
• Regenerative medicine
• Genetics

Background:

• Duchenne muscular dystrophy (DMD) is a severe genetic disorder causing progressive muscle degeneration and reduced lifespan.
• The golden retriever dog model accurately mimics human DMD pathology, including dystrophin absence and severe motility loss.
• Current treatments for DMD are limited, highlighting the need for novel therapeutic approaches.

Purpose of the Study:

• To evaluate the therapeutic potential of canine mesoangioblasts for Duchenne muscular dystrophy.
• To assess the impact of intra-arterial mesoangioblast delivery on dystrophin expression and muscle function in a canine DMD model.

Main Methods:

• Intra-arterial transplantation of wild-type canine mesoangioblasts (vessel-associated stem cells) into affected dogs.
• Assessment of dystrophin protein expression, muscle morphology, and functional recovery.
• Measurement of single-fiber contraction force to quantify functional improvement.

Main Results:

• Extensive recovery of dystrophin expression was observed following mesoangioblast delivery.
• Restored muscle morphology and significant improvement in muscle function, including contraction force.
• Preservation of active motility and remarkable clinical amelioration in treated animals.

Conclusions:

• Canine mesoangioblasts demonstrate significant therapeutic potential for Duchenne muscular dystrophy.
• Intra-arterial delivery of mesoangioblasts can restore dystrophin and improve muscle function.
• Mesoangioblasts are promising candidates for future stem cell therapy in human DMD patients.